MAPT and Alzheimer disease: Notably, NEP is reduced and inversely correlated with levels of CSF Aβ and tau in AD patients, and downregulation of NEP is associated with the progression of AD neuropathology, supporting the key role of this enzyme in protection from AD neuropathology [220,221].